Related Experiment Video
Updated: Mar 29, 2026
Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells
Published on: August 1, 2025
Gene Expression Profile of Dendritic Cell-Tumor Cell Hybrids Determined by Microarrays and Its Implications for
Jens Dannull1, Chunrui Tan2, Christine Farrell3
1Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA.
Background:
Dendritic cell- (DC-) tumor fusion cells stimulate effective in vivo antitumor responses. However, therapeutic approaches are dependent upon the coadministration of exogenous 3rd signals. The purpose of this study was to determine the mechanisms for inadequate 3rd signaling by electrofused DC-tumor cell hybrids.
Methods:
Murine melanoma cells were fused with DCs derived from C57BL/6 mice. Quantitative real-time PCR (qPCR) was used to determine relative changes in Th (T helper) 1 and Th2 cytokine gene expression. In addition, changes in gene expression of fusion cells were determined by microarray. Last, cytokine secretion by fusion cells upon inhibition of signaling pathways was analyzed by ELISA.
Results:
qPCR analyses revealed that fusion cells exhibited a downregulation of Th1 associated cytokines IL-12 and IL-15 and an upregulation of the Th2 cytokine IL-4. Microarray studies further showed that the expression of chemokines, costimulatory molecules, and matrix-metalloproteinases was deregulated in fusion cells. Lastly, inhibitor studies demonstrate that inhibition of the PI3K/Akt/mTOR signaling pathway could restore the secretion of bioactive IL-12p70 by fusion cells.
Conclusion:
Our results suggest that combining fusion cell-based vaccination with administration of inhibitors of the PI3K/Akt/mTOR signaling pathway may enhance antitumor responses in patients.
Insights
Electrofused dendritic cell-tumor hybrids show suppressed antitumor signaling. Inhibiting the PI3K/Akt/mTOR pathway can restore crucial cytokine secretion, enhancing potential cancer immunotherapies.
Area of Science:
- Immunology
- Cancer Biology
- Cellular Signaling
Background:
- Dendritic cell- (DC-) tumor fusion cells are potent inducers of antitumor immunity.
- Current therapeutic strategies require external "3rd signals" for optimal efficacy.
- Understanding the intrinsic signaling defects in these hybrids is critical.
Purpose of the Study:
- To elucidate the mechanisms underlying inadequate 3rd signaling in electrofused DC-tumor cell hybrids.
- To identify molecular targets for enhancing DC-tumor hybrid immunotherapy.
Main Methods:
- Fusion of murine melanoma cells with C57BL/6 mouse-derived DCs.
- Quantitative real-time PCR (qPCR) for Th1/Th2 cytokine gene expression analysis.
- Microarray analysis for global gene expression profiling of fusion cells.
- Enzyme-linked immunosorbent assay (ELISA) to assess cytokine secretion after pathway inhibition.
Main Results:
- Fusion cells displayed reduced expression of Th1 cytokines (IL-12, IL-15) and increased Th2 cytokine (IL-4) expression.
- Microarray revealed dysregulated expression of chemokines, costimulatory molecules, and matrix-metalloproteinases.
- Inhibition of the PI3K/Akt/mTOR pathway restored secretion of bioactive IL-12p70.
Conclusions:
- DC-tumor fusion cells exhibit an intrinsic Th1/Th2 cytokine imbalance.
- The PI3K/Akt/mTOR pathway is a key regulator of IL-12p70 secretion in these hybrids.
- Combining fusion cell vaccination with PI3K/Akt/mTOR inhibitors may improve antitumor responses.
